Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
CHICAGO, March 31, 2016 -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced the rollout of three large scale webinars by the FHC Education Team.
Developed to educate U.S. healthcare providers on reimbursability via the Affordable Care Act (ACA), the first webinar and accompanying materials were created with assistance from FHC’s partners the National Coalition of STD Directors (NCSD) and the National Family Planning and Reproductive Health Association (NFPRHA). These resources provide information and education to help women in the U.S. gain more affordable access to FC2 through ACA and/or Medicaid.
A separate webinar was held in partnership with The Southeast AIDS Education and Training Center (SEAETC) to provide FC2 refresher facts and updates. FHC also offered a comprehensive webinar update on FC2, with a focus on FC2 in the prevention of Zika, to the Regional Resource Network Program at the U.S. Department of Health and Human Services’ (HHS) ten regional offices.
On March 21, 2016, the first issue of the FHC U.S. Public Health Newsletter was distributed to more than 3,000 public health professionals. The newsletter will be issued bi-monthly and will alternate with a U.S. retail/commercial sector newsletter, launching in April 2016.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123
